Moderna 儘管第二季業績優於預期，但受臨床試驗受挫影響股價走低 (MRNA:NASDAQ)
· seekingalpha.com
Moderna (MRNA) 宣布其諾羅病毒疫苗第三期臨床試驗遭遇挫折，導致其股價下跌，即便其 2026 年第二季業績超出市場預期。請點此閱讀更多。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...